Gilead is not buying Achillion

Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) entered a worldwide license and
collaboration agreement with Janssen Pharmaceuticals to develop one of
Achillion’s hepatitis C virus treatments but the stock price fell $1.63 to close at $9.05 after
rumors that Gilead Sciences Inc. (Nasdaq: GILD) was buying Achilion were quashed. Gilead stock slipped 39 cents to close at $110.17.